Table 5.
Subgroup Analysisa
| Subgroup | Single-Center Cohort | Multicenter Cohort | |||||
|---|---|---|---|---|---|---|---|
| Cases | Events (%) | Cases | Events (%) | Crude HR (95% CI)b | P-value | P for interaction | |
| Sex | 0.013 | ||||||
| Male | 12,690 | 6126 (48.3%) | 13,045 | 8893 (68.2%) | 1.52 (1.48–1.58) | <0.001 | |
| Female | 2965 | 1190 (40.1%) | 3398 | 2142 (63.0%) | 1.68 (1.57–1.81) | <0.001 | |
| mUICC staging | <0.001 | ||||||
| Stage I | 2626 | 527 (20.1%) | 2532 | 1058 (41.8%) | 2.13 (1.91–2.36) | <0.001 | |
| Stage II | 6176 | 1991 (32.2%) | 6168 | 3273 (53.1%) | 1.65 (1.56–1.74) | <0.001 | |
| Stage III | 4712 | 2954 (62.7%) | 4147 | 3267 (78.8%) | 1.29 (1.23–1.36) | <0.001 | |
| Stage IVA | 1291 | 1100 (85.2%) | 1920 | 1807 (94.1%) | 1.32 (1.23–1.42) | <0.001 | |
| Stage IVB | 850 | 744 (87.5%) | 1627 | 1586 (97.5%) | 1.34 (1.23–1.46) | <0.001 | |
| Child-Pugh class | <0.001 | ||||||
| Class A | 12,126 | 4738 (39.1%) | 11,476 | 6717 (58.5%) | 1.55 (1.49–1.61) | <0.001 | |
| Class B | 2904 | 2156 (74.2%) | 3469 | 3039 (87.6%) | 1.26 (1.19–1.33) | <0.001 | |
| Class C | 510 | 391 (76.7%) | 747 | 686 (91.8%) | 1.53 (1.35–1.73) | <0.001 | |
| Type of initial treatment | <0.001 | ||||||
| Curativec | 6586 | 1523 (23.1%) | 5282 | 1945 (36.8%) | 1.58 (1.47–1.67) | <0.001 | |
| Non-curatived | 7626 | 4533 (59.4%) | 8070 | 6222 (77.1%) | 1.27 (1.22–1.32) | <0.001 | |
| Best supportive care | 1443 | 1260 (87.3%) | 3091 | 2868 (92.8%) | 0.75 (0.70–0.80) | <0.001 | |
Notes: aMissing data was imputed. bCrude hazard ratio for multicenter vs single-center cohort. cCurative treatment was defined as surgical resection, liver transplantation, and local ablation therapy. dNon-curative treatment was defined as TACE/TARE, radiotherapy, and systemic therapy.
Abbreviations: CI, confidence interval; HR, hazard ratio; mUICC, modified Union for International Cancer Control.